Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Enkeltbolus ikke-immunogen stafylokinase hos pasienter med akutt iskemisk slag innen 4,5–24 timer etter symptomdebut (FRIDA-CT)

30. september 2026 oppdatert av: Supergene, LLC

En multikenter, dobbeltblind, randomisert, placebokontrollert studie av effektiviteten og sikkerheten til rekombinant ikke-immunogen stafylokinase hos pasienter med akutt iskemisk slag innen 4,5–24 timer etter symptomdebut (FRIDA-CT)

Multicenter, double-blind, randomized, placebo-controlled phase III clinical trial. At the clinical sites, patients with acute ischemic stroke within 4.5-24 hours of symptom onset will be randomized to receive a single bolus injection of the recombinant non-immunogenic staphylokinase (Fortelyzin®, LLC "SuperGene", Russia) or placebo.

Studieoversikt

Detaljert beskrivelse

The current guidelines recommended intravenous thrombolysis as the first-line treatment for acute large vessel occlusion of anterior circulation stroke within 4.5 hours of stroke onset. However, a majority of patients arrive in the hospital outside the 4.5-hour time window, who could not receive intravenous thrombolysis.

In 2020, the non-immunogenic staphylokinase was registered in Russia for the acute ischemic stroke treatment within 4,5 h after the onset of symptoms. In the FRIDA randomized clinical trial the non-immunogenic staphylokinase was non-inferior to alteplase for patients with acute ischaemic stroke. Mortality, symptomatic intracranial haemorrhage, and serious adverse events did not differ significantly between groups. Non-immunogenic staphylokinase is easy to administer with a rapid single bolus of 10 mg regardless patients' bodyweight, simplifying clinical use. In 2024, the non-immunogenic staphylokinase has been included in the updated Russian clinical guidelines for the acute ischemic stroke treatment.

A rapid (10 s) single bolus of the non-immunogenic staphylokinase in patients with acute ischemic stroke may provide significant advantages over a one-hour alteplase administration in the more rapid reperfusion in the first 24 hours after thrombolysis and a greater number of good functional outcomes. It can be assumed that the non-immunogenic staphylokinase usage in patients with acute ischemic stroke outside the 4.5-hour therapeutic window will lead to the restoration of collateral blood flow in the penumbra in comparison with standard medical management.

Therefore, FRIDA-CT trial is aimed to investigate the efficacy and safety of the non-immunogenic staphylokinase within the time window of 4.5-24 hours, wake-up stroke or no witness stroke in patients who had an acute ischaemic stroke with salvageable tissue due to large vessel occlusion.

In the multicenter, double-blind, randomized, placebo-controlled phase III clinical trial patients who had an acute ischaemic stroke due to anterior circulation large vessel occlusion (internal carotid artery, middle cerebral artery M1 and M2 segments) within 4.5-24 hours from last known well (including wake-up stroke and no witness stroke) and with salvageable tissue (ischaemic core volume <70 mL, mismatch ratio ≥1.8 and mismatch volume ≥15 mL) based on CT perfusion or MRI perfusion-weighted imaging (PWI) will be included and randomised to the non-immunogenic staphylokinase, 10 mg (single bolus) regardless patient's bodyweight or placebo group. Patients who are intended for direct thrombectomy will be excluded from the trial. Follow-up period will be 90 days.

Studietype

Intervensjonell

Registrering (Antatt)

990

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

  • Navn: Nikolay A. Shamalov, MD, prof
  • Telefonnummer: +7 (499) 936-99-37
  • E-post: shamalovn@gmail.com

Studer Kontakt Backup

Studiesteder

      • Chelyabinsk, Russland
        • Rekruttering
        • Chelyabinsk Regional Clinical Hospital No. 3
        • Ta kontakt med:
        • Hovedetterforsker:
          • Dmitry V. Popov, PhD
      • Irkutsk, Russland, 664079
        • Rekruttering
        • Irkutsk Regional Clinical Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Ivan V. Korobeynikov, PhD
      • Kazan', Russland, 420101
        • Har ikke rekruttert ennå
        • Interregional Clinical and Diagnostic Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Dina R. Khasanova, MD, Prof
      • Krasnodar, Russland, 350086
        • Rekruttering
        • S.V. Ochapovsky Research Institute - Regional Clinical Hospital No. 1
        • Ta kontakt med:
        • Hovedetterforsker:
          • Ludmila V. Timchenko, MD, prof
      • Krasnogorsk, Russland, 143408
        • Har ikke rekruttert ennå
        • Krasnogorsk Clinical Hospital
        • Ta kontakt med:
          • Svetlana V. Alexandrova
          • Telefonnummer: +7 (498) 602-03-73
          • E-post: clairalex@mail.ru
        • Hovedetterforsker:
          • Svetlana V. Alexandrova
      • Moscow, Russland, 117997
        • Har ikke rekruttert ennå
        • N.I. Pirogov Russian National Research Medical University
        • Ta kontakt med:
        • Hovedetterforsker:
          • Larisa L. Korsunskaya, MD, Prof
      • Moscow, Russland, 108814
        • Har ikke rekruttert ennå
        • Moscow Multidisciplinary Clinical Center "Kommunarka"
        • Ta kontakt med:
        • Hovedetterforsker:
          • Denis N. Protsenko, PhD
      • Nizhny Novgorod, Russland, 603126
        • Har ikke rekruttert ennå
        • N.A. Semashko Nizhny Novgorod Regional Clinical Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Valentina N. Nesterova, PhD
      • Orenburg, Russland
        • Rekruttering
        • V.I. Voynov Orenburg Regional Clinical Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Alexandr N. Chirkov, PhD
      • Saint Petersburg, Russland, 193079
        • Rekruttering
        • St. Petersburg Hospital for War Veterans
        • Ta kontakt med:
        • Hovedetterforsker:
          • Maria A. Privalova, PhD
      • Saint Petersburg, Russland, 194291
        • Rekruttering
        • Leningradskaya Regional Clinical Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Natalya V. Zhukovskaya, MD, prof
      • Sergiyev Posad, Russland, 141301
        • Har ikke rekruttert ennå
        • Sergiev Posad District Hospital
        • Ta kontakt med:
          • Anton G. Koledinsky, MD, PhD
          • Telefonnummer: +7 (496) 542-22-84
          • E-post: koledant@mail.ru
        • Hovedetterforsker:
          • Anton G. Koledinsky, MD, PhD
      • Tver', Russland, 170036
        • Rekruttering
        • Tver Regional Clinical Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Ksenia V. Khoroshavina
      • Ulyanovsk, Russland
        • Rekruttering
        • Ulyanovsk Regional Clinical Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Irina V. Greshnova, PhD
      • Volgograd, Russland, 400138
        • Rekruttering
        • City Clinical Hospital of Emergency Medical Care No. 25
        • Ta kontakt med:
        • Hovedetterforsker:
          • Eduard A. Ponomarev, MD, prof
      • Yekaterinburg, Russland, 620102
        • Rekruttering
        • Sverdlovsk Regional Clinical Hospital No. 1
        • Ta kontakt med:
        • Hovedetterforsker:
          • Andrey M. Alasheev, MD, prof
    • Ryazan Oblast
      • Ryazan, Ryazan Oblast, Russland, 390039
        • Har ikke rekruttert ennå
        • Ryazan Regional Clinical Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Sergei B. Aksentyev, PhD

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Men and women aged 18 years and over;
  2. Acute ischemic stroke symptom onset between 4.5 to 24 hours prior to enrolment, including wake-up stroke and unwitnessed stroke, onset time refers to "last-seen normal time";
  3. Pre-stroke modified Rankin scale (mRS) score≤1;
  4. Internal carotid artery, middle cerebral artery M1 or M2 occlusion confirmed by CT/MRI, internal carotid artery, middle cerebral artery M1 or M2 being responsible for signs and symptoms of acute ischemic stroke;
  5. Neuroimaging: target mismatch profile on CT or MRI perfusion: ischemic core volume <70 mL, mismatch ratio≥1.8 and mismatch volume≥15 mL;
  6. Alberta Stroke Program Early CT score (ASPECTS) > 6;
  7. Baseline National Institutes of Health Stroke Scale (NIHSS) 6-25 (inclusive);
  8. The patient is not planned or cannot undergo thrombectomy or intravenous thrombolysis in accordance with the current version of the Clinical Guidelines;
  9. Written informed consent from patients or their legally authorized representatives.

Exclusion Criteria:

  1. Acute ischemic stroke within 4,5 h after symptom onset;
  2. Intended to proceed to endovascular treatment;
  3. Known hypersensitivity to the non-immunogenic staphylokinase;
  4. Convulsive seizures at the onset of the disease, if there is no certainty that the seizure is a clinical manifestation of acute ischemic stroke;
  5. Persistent blood pressure elevation (systolic ≥185 mmHg or diastolic ≥110 mmHg), and the inability to reduce systolic blood pressure below 180 mmHg or diastolic blood pressure below 105 mmHg;
  6. Blood glucose <2.8 or >22.2 mmol/L (after blood glucose level correction to the specified values, inclusion of the patient in the study is possible);
  7. Neuroimaging (CT, MRI) signs of intracranial hemorrhage, brain tumor, arteriovenous malformation, brain abscess, cerebral aneurysm;
  8. Subarachnoid hemorrhage;
  9. Major bleeding currently or within the past 6 months;
  10. Surgery on the brain or spinal cord in the last 2 months;
  11. Punctures of non-compressible arteries and veins in the last 7 days;
  12. Gastrointestinal or genitourinary bleeding in the last 3 weeks. Confirmed exacerbations of gastric ulcer and duodenal ulcer in the last 3 months;
  13. Platelet count below 100,000/mm3;
  14. Previous stroke or severe traumatic brain injury within 3 months;
  15. Unable to perform CT or MRI;
  16. History of hemorrhagic stroke or stroke of unspecified genesis;
  17. Multiple arterial occlusion (bilateral MCA occlusion, MCA occlusion accompanied with basilar occlusion);
  18. Concomitant use of indirect oral anticoagulants (warfarin) with INR > 1.7;
  19. Taking direct anticoagulants (heparin, heparinoids) in the previous 48 hours with an APTT value above normal;
  20. Taking new oral anticoagulants in the previous 48 hours with a thrombin time value above normal and the impossibility of administering the specific antagonist idarucizumab (for dabigatran) or the presence of anti-Xa activity (for rivaroxaban, apixaban and edoxaban).
  21. Severe liver disease, including liver failure, liver cirrhosis, portal hypertension (with esophageal varices), active hepatitis;
  22. Acute pancreatitis;
  23. Bacterial endocarditis, pericarditis;
  24. Arterial aneurysms, malformations of arteries and veins. Suspected dissecting aortic aneurysm;
  25. Cancer with an increased risk of bleeding;
  26. Major surgeries or severe injuries within the last 14 days, minor surgeries or invasive procedures within the last 10 days;
  27. Prolonged or traumatic cardiopulmonary resuscitation (more than 2 minutes);
  28. Hemorrhagic diathesis, including renal and hepatic failure;
  29. Data on bleeding or acute trauma (fracture) at the time of examination;
  30. Pregnant women, nursing mothers, or reluctant to use effective contraceptive measures during the period of trial.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Trippel

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Placebo komparator: Placebo

Placebo

Placebo is given as a single intravenous bolus (within 5-10 seconds) immediately upon randomization

Eksperimentell: Non-immunogenic staphylokinase

The non-immunogenic staphylokinase is given as a single intravenous bolus, 10 mg (within 5-10 seconds) immediately upon randomization regardless patient's bodyweight

The non-immunogenic staphylokinase is given as a single intravenous bolus, 10 mg (within 5-10 seconds) immediately upon randomization regardless patient's bodyweight

Andre navn:
  • Fortelyzin®

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Excellent functional outcome
Tidsramme: 90 days

The number of patients with excellent functional outcome defined as an mRS score 0-1 at 90 days

90 days

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Ordinal distribution of mRS
Tidsramme: 90 days

Ordinal distribution of mRS at 90 days

90 days
Functional independence outcome
Tidsramme: 90 days

The number of patients with functional independence defined by an mRS score 0-2 point at 90 days

90 days
NIHSS change from baseline
Tidsramme: 7-14 days

NIHSS median change from baseline on discharge

7-14 days
The rate of improvement on reperfusion
Tidsramme: 24 hours

The number of patients with recanalization of 2 and 3 points on the arterial occlusion scale (rAOL) 24 hours after drug administration according to CT (MRI) angiography, where 0 points - complete occlusion, 3 points - complete recanalization.

24 hours
All-cause mortality
Tidsramme: 90 days

Rate of all-cause mortality within 90 days

90 days
Poor functional outcome
Tidsramme: 90 days

The number of patients with poor functional outcome defined by an mRS score 5-6 point at 90 days

90 days

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Hemorrhagic transformation
Tidsramme: 24 hours

Rate of hemorrhagic transformation according to The Heidelberg Bleeding Classification within 24 hours

24 hours
Symptomatic intracranial hemorrhage
Tidsramme: 24 hours

Rate of symptomatic intracranial hemorrhage (sICH) (as defined by The European Cooperative Acute Stroke Study III criteria [ECASSIII] and Safe Implementation of Thrombolysis in Stroke-Monitoring Study [SITS-MOST]) within 24 hours

24 hours
Major bleeding
Tidsramme: 90 days

Rate of major bleeding at 90 days (as defined by the Bleeding Academic Research Consortium (BARC) scale: type 3 and type 5)

90 days
Serious adverse events (SAEs)
Tidsramme: 90 days

Rate of serious adverse events (SAEs) within 90 days

90 days

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Hovedetterforsker: Nikolay A. Shamalov, MD, prof, Federal Center for Brain and Neurotechnology of the Federal Medical and Biological Agency of Russia
  • Studieleder: Sergey S. Markin, MD, prof, LLC "SuperGene"

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

9. juni 2026

Primær fullføring (Antatt)

1. november 2028

Studiet fullført (Antatt)

1. januar 2029

Datoer for studieregistrering

Først innsendt

23. desember 2025

Først innsendt som oppfylte QC-kriteriene

23. desember 2025

Først lagt ut (Faktiske)

8. januar 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

1. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

30. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

The funder of the study is committed to the responsible sharing of data from FRIDA-CT trail. Data will be provided to any qualified investigator on reasonable request. Deidentified participant data will be available after the publication of the results of the completed study on request to the corresponding author.

IPD-delingstidsramme

within 90 days after request

Tilgangskriterier for IPD-deling

Proposals will be reviewed and approved by the funder and Data and Safety Monitoring Board. Once the proposal has been approved, data can be transferred through a secure online platform after the signing of a data access agreement and a confidentiality agreement.

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE
  • ICF
  • CSR

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere